1. Introduction {#j_med-2017-0050_s_001}
===============

Colorectal cancer accounting for 1,000,000 new cases per year is one of the most diagnosed malignant carcinoma world-wide \[[@j_med-2017-0050_ref_001]\]. Its incidence ranks the third just behind lung cancer and breast cancer. In China, colorectal cancer is one of the leading causes of cancer related death with an incidence rate of 13.6/100,000 for males and 9.2/100,000 for females which is still on the rise \[[@j_med-2017-0050_ref_002]\]. The prognosis of colorectal cancer is relatively good for early stage patients. However, the long-term survival rate is very low for advanced metastatic disease. Therefore, early diagnosis is important for improving the survival of patients with colorectal cancer. Serum biomarkers for colorectal cancer screening or diagnosis is generally used clinically such as CEA, CA199 and *et al* \[[@j_med-2017-0050_ref_003], [@j_med-2017-0050_ref_004]\]. Cytokertation 20 (CK20) protein is widely used as a serum biomarker for cancer screening or diagnosis. However, the efficacy of using the serum level of CK20mRNA as a biomarker for colorectal cancer diagnosis is not clear according to the previously published studies with small sample sizes. Therefore, we performed this meta-analysis to further evaluate the diagnostic value of CK20mRNA level in serum for colorectal cancer.

2. Material and methods {#j_med-2017-0050_s_002}
=======================

2.1. Studies selection {#j_med-2017-0050_s_002_s_001}
----------------------

Clinical studies related to serum CK20 mRNA for colorectal cancer diagnosis were searched in the databases of Pubmed, Cochrane Library, Embase, ISI Web of Knowledge, CNKI, and Wanfang. The "colorectal cancer/CRC", "colon cancer", "rectal cancer", "colorectal carcinoma", "colorectal neoplasm", "colorectal tumor", "colon carcinoma", "rectal carcinoma", "colon neoplasm", " rectal neoplasm", "colon tumor", "rectal tumor", "CK20", "cytokertation 20" were used as the MeSH and free text words when searching the databases. The inclusion criteria were: colorectal cancer patients with histology or cytology conformation; the CK20 mRNA expression in serum was detected by real-time quantitative PCR (RT-qPCR) or other confirmed methods; the patients distribution of true positive(tp), false positive(fp), false negative(fn) and true negative(tn) in colorectal patients and controls could be drawn from the original included publications. All potential relevant studies were assessed in details, and all citations of the included articles were further evaluated in order to identify additional suitable studies. The publication searching was done by two reviewers independently and cross checked.

2.2. Data extraction from the original studies {#j_med-2017-0050_s_002_s_002}
----------------------------------------------

The data and main information of each include publications were extracted by two authors independently and checked by the third reviewer. The sample size, first and corresponding authors, number of subjects distributed to tp, fp, fn and tn were carefully extracted from the included publications.

2.3. Statistical analysis {#j_med-2017-0050_s_002_s_003}
-------------------------

The statistical analysis was done by MetaDiSc1.4 (<http://www.biomedsearch.com>) software. Chi-square and I^2^ test were used to calculate the statistical heterogeneity among the included studies. Fixed or random effect method was used to pool the sensitivity, specificity, +LR, −LR, and DOR according to the statistical heterogeneity results. The publication bias was evaluated by funnel plot and Egger's line regression test.

3. Results {#j_med-2017-0050_s_003}
==========

3.1. General character of the included 19 publications {#j_med-2017-0050_s_003_s_001}
------------------------------------------------------

After searching the related electronic databases, 19 studies \[[@j_med-2017-0050_ref_005]-[@j_med-2017-0050_ref_023]\] met the inclusion criteria and were finally included in this meta-analysis. The publication searching procedure is demonstrated in [Figure 1](#j_med-2017-0050_fig_001){ref-type="fig"}. The publication year ranges from 1999 to 2012. Serum CK20 mRNA was examined by RT-qPCR and FQ-PCR assay in 15 and 4 studies respectively. The general information of the included 19 publications is demonstrated in [Table 1](#j_med-2017-0050_tab_001){ref-type="table"}.

![The publication searching flow chart](med-12-347-g001){#j_med-2017-0050_fig_001}

###### 

The general characters of the included 19 publications

  Author                                           Year   Sample size   Distribution   Control type   Country   Methods                                
  ------------------------------------------------ ------ ------------- -------------- -------------- --------- --------- ------------------ --------- ---------
  Richard Q\[[@j_med-2017-0050_ref_005]\]          1999   170           35             1              65        69        Population based   Britain   RT-qPCR
  Chausovsky G\[[@j_med-2017-0050_ref_006]\]       1999   57            15             0              20        22        Population based   Israel    RT-qPCR
  Lin GL\[[@j_med-2017-0050_ref_007]\]             2002   67            23             0              24        20        Mixed              China     RT-qPCR
  Sun JW\[[@j_med-2017-0050_ref_008]\]             2004   62            19             0              23        20        Population based   China     RT-qPCR
  Cui M\[[@j_med-2017-0050_ref_009]\]              2004   122           62             0              40        20        Population based   China     RT-qPCR
  Zeng QG\[[@j_med-2017-0050_ref_010]\]            2004   89            41             6              12        30        Hospital based     China     RT-qPCR
  Yin HZ\[[@j_med-2017-0050_ref_011]\]             2005   57            34             0              13        10        Population based   China     FQ-PCR
  Yin HZ\[[@j_med-2017-0050_ref_011]\]             2005   57            34             0              13        10        Hospital based     China     FQ-PCR
  Dandachi N\[[@j_med-2017-0050_ref_017]\]         2005   134           46             17             36        35        Mixed              Austria   RT-qPCR
  Guo J\[[@j_med-2017-0050_ref_018]\]              2005   50            31             0              9         10        Hospital based     China     FQ-PCR
  Xu D\[[@j_med-2017-0050_ref_019]\]               2006   198           46             2              122       28        Population based   China     RT-qPCR
  Katsumata K\[[@j_med-2017-0050_ref_020]\]        2006   54            18             0              22        14        Population based   Japan     RT-qPCR
  Wang ZC\[[@j_med-2017-0050_ref_012]\]            2007   211           35             0              101       73        Mixed              China     FQ-PCR
  Shen C\[[@j_med-2017-0050_ref_021]\]             2008   281           74             21             82        104       Mixed              China     RT-qPCR
  Lagoudianakis EE\[[@j_med-2017-0050_ref_022]\]   2009   58            28             0              14        14        Population based   Greece    RT-qPCR
  Wong SC\[[@j_med-2017-0050_ref_023]\]            2009   342           62             3              70        207       Mixed              China     FQ-PCR
  Wu F\[[@j_med-2017-0050_ref_013]\]               2009   142           44             0              48        50        Population based   China     RT-qPCR
  Chen P\[[@j_med-2017-0050_ref_014]\]             2009   56            18             0              18        20        Population based   China     RT-qPCR
  Chen P\[[@j_med-2017-0050_ref_014]\]             2009   57            18             1              18        10        Hospital based     China     RT-qPCR
  He Q\[[@j_med-2017-0050_ref_015]\]               2010   151           49             0              52        50        Population based   China     RT-qPCR
  Li LH\[[@j_med-2017-0050_ref_016]\]              2012   110           48             3              32        27        Hospital based     China     RT-qPCR
  Li LH\[[@j_med-2017-0050_ref_016]\]              2012   110           48             0              32        30        Population based   China     RT-qPCR

3.2. Pooled sensitivity {#j_med-2017-0050_s_003_s_002}
-----------------------

Due to significant statistical heterogeneity across the studies, the diagnostic sensitivity was pooled by random effect model (I^2^=85.6%). The pooled diagnostic sensitivity of CK20 mRNA in serum as a biomarker for colorectal cancer was 0.49 with the 95% CI of 0.46 to 0.51 through random effect method, [Figure 2](#j_med-2017-0050_fig_002){ref-type="fig"}.

![The forest plot of diagnostic sensitivity for serum CK20 mRNA in diagnosis of colorectal cancer](med-12-347-g002){#j_med-2017-0050_fig_002}

3.3. Pooled specificity {#j_med-2017-0050_s_003_s_003}
-----------------------

Statistical significance was also found in diagnostic specificity (I^2^=82.2%). The data was pooled by random effect method. The pooled specificity was 0.94 with the 95%CI of 0.92-0.96, [Figure 3](#j_med-2017-0050_fig_003){ref-type="fig"}.

![The forest plot of diagnostic specificity for serum CK20 mRNA in diagnosis of colorectal cancer](med-12-347-g003){#j_med-2017-0050_fig_003}

3.4. Pooled +LR and −LR {#j_med-2017-0050_s_003_s_004}
-----------------------

Significant heterogeneity was found in +LR and −LR (I^2^=74.9% and 81.9%). The pooled +LR and −LR were 10.90 (95%CI:5.78 to 20.55) and 0.51 (95%CI:0.45 to 0.57) respectively for serum CK20 mRNA in the diagnosis of colorectal cancer, [Figure 4](#j_med-2017-0050_fig_004){ref-type="fig"}.

![The forest plot of diagnostic +LR and −LR for serum CK20 mRNA in diagnosis of colorectal cancer](med-12-347-g004){#j_med-2017-0050_fig_004}

3.5. Pooled DOR {#j_med-2017-0050_s_003_s_005}
---------------

With statistical heterogeneity, the DOR was calculated by random effect method (I^2^=64.2%). The pooled DOR was 22.31 with the 95% CI of 11.65 to 42.71, [Figure 5](#j_med-2017-0050_fig_005){ref-type="fig"}.

![The forest plot of DOR for serum CK20 mRNA in diagnosis of colorectal cancer.](med-12-347-g005){#j_med-2017-0050_fig_005}

3.6. Pooled ROC {#j_med-2017-0050_s_003_s_006}
---------------

The pooled area under the ROC curve was 0.72 for CK20 mRNA in serum as a biomarker for colorectal cancer, [Figure 6](#j_med-2017-0050_fig_006){ref-type="fig"}.

![ROC cure of CK20 mRNA in serum as biomarker for colorectal cancer diagnosis.](med-12-347-g006){#j_med-2017-0050_fig_006}

3.7. Subgroup analysis {#j_med-2017-0050_s_003_s_007}
----------------------

We performed subgroup analysis according to control type and CK20 mRNA detection methods. The pooled sensitivity, specificity, +LR, −LR, DOR and AUC of the population based control group, hospital based control group, RT-qPCR group and FQ-PCR group are shown in [Table 2](#j_med-2017-0050_tab_002){ref-type="table"}. The diagnostic value changed a little for different subgroup analysis.

###### 

Subgroup analysis according to the control type and CK20 mRNA detection methods

  Factors            Sen(95%CI)        Spe(95%CI)        +LR(95%CI)           -LR(95%CI)        DOR(95%CI)            AUC
  ------------------ ----------------- ----------------- -------------------- ----------------- --------------------- ------
  Control type                                                                                                        
  Population based   0.47(0.44-0.50)   0.99(0.98-1.00)   15.51(7.81-30.83)    0.51(0.44-0.60)   29.37(14.30-60.34)    0.86
  Hospital based     0.67(0.61-0.73)   0.90(0.82-0.95)   5.61(3.21-9.82)      0.36(0.26-0.49)   17.44(8.46-35.94)     0.88
  Methods                                                                                                             
  RT-qPCR            0.49(0.46-0.52)   0.92(0.89-0.94)   8.30(4.37-15.60)     0.53(0.47-0.60)   16.60(8.42-32.75)     0.71
  FQ-PCR             0.49(0.44-0.54)   0.99(0.77-1.00)   26.77(11.17-64.15)   0.41(0.27-0.61)   59.21(23.64-148.29)   0.95

3.8. Publication bias {#j_med-2017-0050_s_003_s_008}
---------------------

The Deeks' funnel plot showed no significant publication bias in the aspect of serum CK20 mRNA as a biomarker for colorectal cancer diagnosis (t=0.56, P=0.58), [Figure 7](#j_med-2017-0050_fig_007){ref-type="fig"}.

![Publication bias evaluated by Deeks' funnel plot](med-12-347-g007){#j_med-2017-0050_fig_007}

4. Discussion {#j_med-2017-0050_s_004}
=============

Colorectal cancer, also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum. It is one of the leading causes of cancer related death world-wide \[[@j_med-2017-0050_ref_024], [@j_med-2017-0050_ref_025]\]. Population based colorectal cancer screening for high risk patients is a key method for identifying early stage patients and improving the prognosis. The National Comprehensive Cancer Network (NCCN) colorectal cancer guideline recommends fecal occult blood tests plus colonoscopy for colorectal cancer screening \[[@j_med-2017-0050_ref_026], [@j_med-2017-0050_ref_027]\]. Colonoscopy examination for colorectal cancer diagnosis has high specificity and sensitivity. However, colonoscopy examination is mildly invasive, expensive, and a complex operation procedure, which is not suitable for population based screening. It was believed that the ideal colorectal cancer screening or early diagnosis method should be of high sensitivity, high specificity, non-invasive, and easy to perform. Serum biomarkers are easy to access, non-invasive, less expensive and easy to test, which makes them suitable for colorectal cancer screening or diagnosis \[[@j_med-2017-0050_ref_028]\].

CK20 is a member of the intermediate filament protein family and a prominent component of the intestinal epithelium. CK20 expression is confined to astrointestinal epithelium, urothelium, and Merkel cells of the epidermis, as well as malignancies that originate from the aforementioned sites \[[@j_med-2017-0050_ref_029], [@j_med-2017-0050_ref_030]\]. CK20 mRNA expression in serum detected by RT-qPCR was widely investigated for colorectal cancer screening. For most studies published in the previous years, CK20 mRNA was elevated in colorectal cancer patients compared to healthy controls or benign colorectal disease patients. However, its clinical value as a biomarker for colorectal cancer diagnosis is not clear for different study design. And, because of small sample size for each individual study, the results were inconclusive and clinical value was limited. To further assess the diagnostic value of serum CK20 mRNA as a biomarker for colorectal cancer diagnosis or screening, we searched the open published studies related to CK20 mRNA and colorectal cancer diagnosis and performed this meta-analysis. We found that CK20 mRNA almost cannot be detected in the serum of healthy people or benign colorectal disease patients. This made the false positive rate very low. However, the positive rate of serum CK20 mRNA in colorectal patients was also relative low. This made the serum CK20 mRNA a high specificity and low sensitivity biomarker for colorectal cancer diagnosis. Due to the low sensitivity (0.49, 95%CI:0.46-0.51), serum CK20 mRNA is not suitable for colorectal screening especially for the population based trials. However, a very high specificity (0.94, 95%CI: of 0.92-0.96), means that serum CK20 mRNA can be used as a confirmation test for colorectal cancer diagnosis.
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